array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(198) "Intellia Therapeutics to Present Latest Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis on the 2024 AHA Scientific Sessions" ["snippet_en"]=> string(134) "Latest data to be presented will include biomarkers of disease progression and functional capability from the continuing Phase 1 study" ["url"]=> string(220) "https://todaysstocks.com/intellia-therapeutics-to-present-latest-clinical-data-from-the-phase-1-study-of-nexiguran-ziclumeran-nex-z-for-the-treatment-of-transthyretin-attr-amyloidosis-on-the-2024-aha-scientific-sessions/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/7c90f88d-6ab9-4428-abc7-9c41a159fbaa" ["source"]=> string(16) "todaysstocks.com" ["publication_date"]=> string(10) "2024-10-01" ["categories"]=> array(4) { [0]=> string(16) "Customer Privacy" [1]=> string(17) "Academic Research" [2]=> string(13) "Collaboration" [3]=> string(13) "Data Security" } } [1]=> array(7) { ["title_en"]=> string(45) "Dupixent Data Could Scratch A Regulatory Itch" ["snippet_en"]=> string(187) "New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too." ["url"]=> string(81) "https://scrip.citeline.com/SC150882/Dupixent-Data-Could-Scratch-A-Regulatory-Itch" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3afeb543-629a-4ac0-89a5-67d367413c9d" ["source"]=> string(12) "citeline.com" ["publication_date"]=> string(10) "2024-09-11" ["categories"]=> array(3) { [0]=> string(16) "Customer Privacy" [1]=> string(10) "Cybercrime" [2]=> string(13) "Data Security" } } [2]=> array(7) { ["title_en"]=> string(121) "Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies" ["snippet_en"]=> string(154) "ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies Pooled results from the BOREAS and NOTUS..." ["url"]=> string(191) "https://www.globenewswire.com/news-release/2024/09/10/2943464/0/en/Media-Update-ERS-Dupixent-data-reinforce-clinically-meaningful-benefit-from-pooled-analysis-of-two-COPD-phase-3-studies.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/5a6d6a23-90d2-4741-b041-3ebb4dd4143c" ["source"]=> string(17) "globenewswire.com" ["publication_date"]=> string(10) "2024-09-10" ["categories"]=> array(2) { [0]=> string(13) "Collaboration" [1]=> string(13) "Data Security" } } [3]=> array(7) { ["title_en"]=> string(108) "Regeneron Highlights Progress of Its Differentiated Oncology Product Portfolio and Pipeline at WCLC and ESMO" ["snippet_en"]=> string(75) "Regeneron Pharmaceuticals announced the presentation of data from its […]" ["url"]=> string(157) "https://www.tecnomedicina.it/regeneron-evidenzia-i-progressi-del-suo-portafoglio-di-prodotti-oncologici-differenziati-e-della-sua-pipeline-al-wclc-e-allesmo/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/25a5218e-b7c5-4809-81bd-e4268f9191db" ["source"]=> string(16) "tecnomedicina.it" ["publication_date"]=> string(10) "2024-09-10" ["categories"]=> array(1) { [0]=> string(13) "Data Security" } } [4]=> array(7) { ["title_en"]=> string(76) "Pharmaceutical giant Cencora alerts millions of people about its data breach" ["snippet_en"]=> string(149) "Cencora has so far notified more than 1 million people in the United States that their personal and protected health information has been compromised" ["url"]=> string(141) "https://fr.techtribune.net/d2/tech-today/le-geant-pharmaceutique-cencora-alerte-des-millions-de-personnes-sur-sa-violation-de-donnees/944515/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a96d22cd-3345-4032-b406-d38b406c7581" ["source"]=> string(15) "techtribune.net" ["publication_date"]=> string(10) "2024-08-02" ["categories"]=> array(3) { [0]=> string(5) "Legal" [1]=> string(10) "Cybercrime" [2]=> string(13) "Data Security" } } [5]=> array(7) { ["title_en"]=> string(71) "Automating FAIR, Clean Data Generation from Flow Cytometry at Regeneron" ["snippet_en"]=> string(142) "Stay on top of emerging IT trends in biomedicine. Read the latest news on genomics, computational science, and more. Get recent updates today!" ["url"]=> string(113) "http://www.bio-itworld.com/news/2024/06/06/automating-fair-clean-data-generation-from-flow-cytometry-at-regeneron" ["image_url"]=> NULL ["source"]=> string(15) "bio-itworld.com" ["publication_date"]=> string(10) "2024-06-06" ["categories"]=> array(1) { [0]=> string(13) "Data Security" } } [6]=> array(7) { ["title_en"]=> string(31) "Regeneron Pharmaceuticals stock" ["snippet_en"]=> string(135) "Current prices, master data, charts and further information on the Regeneron Pharmaceuticals security (ISIN: US75886F1075, WKN: 881535)" ["url"]=> string(83) "https://www.deraktionaer.de/aktien/kurse/regeneronpharmaceuticals-us75886f1075.html" ["image_url"]=> NULL ["source"]=> string(15) "deraktionaer.de" ["publication_date"]=> string(10) "2024-05-29" ["categories"]=> array(10) { [0]=> string(16) "Customer Privacy" [1]=> string(9) "Investors" [2]=> string(15) "Market Movement" [3]=> string(12) "Stock Market" [4]=> string(24) "Stock Research & Ratings" [5]=> string(10) "Cybercrime" [6]=> string(13) "Data Security" [7]=> string(12) "Going Public" [8]=> string(18) "General Investment" [9]=> string(16) "Share Repurchase" } } [7]=> array(7) { ["title_en"]=> string(80) "Patient Data Provided to Regeneron Pharmaceuticals Leaked in Cencora Data Breach" ["snippet_en"]=> string(185) "On May 23, 2024, Cencora, Inc. filed a notice of data breach with the Attorney General of California after discovering that data provided to the company by Regeneron Pharmaceuticals,..." ["url"]=> string(77) "https://www.jdsupra.com/legalnews/patient-data-provided-to-regeneron-6837781/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/05676978-97b7-48b2-ac94-c7051046af10" ["source"]=> string(11) "jdsupra.com" ["publication_date"]=> string(10) "2024-05-28" ["categories"]=> array(4) { [0]=> string(16) "Customer Privacy" [1]=> string(5) "Legal" [2]=> string(10) "Cybercrime" [3]=> string(13) "Data Security" } } [8]=> array(7) { ["title_en"]=> string(45) "Odronextamab in diffuse large B-cell lymphoma" ["snippet_en"]=> string(82) "Odronextamab data from the pivotal study in relapsed/refractory diffuse large cell" ["url"]=> string(78) "https://arznei-news.de/odronextamab-bei-diffusem-grosszelligen-b-zell-lymphom/" ["image_url"]=> NULL ["source"]=> string(14) "arznei-news.de" ["publication_date"]=> string(10) "2023-12-10" ["categories"]=> array(2) { [0]=> string(17) "Academic Research" [1]=> string(13) "Data Security" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc